DE3856435D1 - Verwendung von Gallsäure-aktiviertem Lipase als Diätsupplement - Google Patents

Verwendung von Gallsäure-aktiviertem Lipase als Diätsupplement

Info

Publication number
DE3856435D1
DE3856435D1 DE3856435T DE3856435T DE3856435D1 DE 3856435 D1 DE3856435 D1 DE 3856435D1 DE 3856435 T DE3856435 T DE 3856435T DE 3856435 T DE3856435 T DE 3856435T DE 3856435 D1 DE3856435 D1 DE 3856435D1
Authority
DE
Germany
Prior art keywords
bile acid
dietary supplement
activated lipase
acid activated
lipase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3856435T
Other languages
English (en)
Other versions
DE3856435T2 (de
Inventor
Jordan J N Tang
Chi-Sun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of DE3856435D1 publication Critical patent/DE3856435D1/de
Publication of DE3856435T2 publication Critical patent/DE3856435T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1216—Other enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/801—Pediatric

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
DE3856435T 1987-11-19 1988-11-18 Verwendung von Gallsäure-aktiviertem Lipase als Diätsupplement Expired - Lifetime DE3856435T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/122,410 US4944944A (en) 1987-11-19 1987-11-19 Dietary compositions and methods using bile salt-activated lipase

Publications (2)

Publication Number Publication Date
DE3856435D1 true DE3856435D1 (de) 2000-11-30
DE3856435T2 DE3856435T2 (de) 2001-03-29

Family

ID=22402581

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3856435T Expired - Lifetime DE3856435T2 (de) 1987-11-19 1988-11-18 Verwendung von Gallsäure-aktiviertem Lipase als Diätsupplement
DE3856214T Expired - Lifetime DE3856214T2 (de) 1987-11-19 1988-11-18 Diätzusammensetzungen und Verfahren zur Verwendung von Gallsäure aktivierter Lipase

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3856214T Expired - Lifetime DE3856214T2 (de) 1987-11-19 1988-11-18 Diätzusammensetzungen und Verfahren zur Verwendung von Gallsäure aktivierter Lipase

Country Status (8)

Country Link
US (1) US4944944A (de)
EP (2) EP0605913B1 (de)
JP (2) JP2592939B2 (de)
AT (2) ATE197127T1 (de)
DE (2) DE3856435T2 (de)
ES (2) ES2152941T3 (de)
GR (1) GR3035093T3 (de)
HK (2) HK1012213A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5200183A (en) * 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5008120A (en) * 1989-07-21 1991-04-16 Snow Brand Milk Products Co., Ltd. Method of preparing iron-fortified beverage
US5173408A (en) * 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
JP2808166B2 (ja) * 1990-04-26 1998-10-08 雪印乳業株式会社 鉄強化飲料の製造方法
US5186961A (en) * 1991-03-15 1993-02-16 North Carolina State University Method and composition for maintaining animals on a keratin-containing diet
US5169666A (en) * 1991-11-14 1992-12-08 The United States Of America As Represented By The Secretary Of Agriculture Preparation of simulated human milk protein by low temperature microfiltration
US5902617A (en) * 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
IS4130A (is) * 1993-03-01 1994-09-02 Ab Astra Ný fjölpeptíð
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
CN1167793C (zh) * 1996-12-06 2004-09-22 阿温蒂斯药物公司 人脂酶样基因编码的多肽及利用它的组合物和方法
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
DK1065936T3 (da) 1998-03-23 2009-11-02 Gen Mills Inc Indkapsling af bestanddele i spiselige produkter
US6399090B1 (en) * 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
CA2334222C (en) * 1998-06-05 2010-02-09 Technion Research And Development Foundation Ltd. Insulin supplemented infant formula
WO2001089553A1 (en) * 1999-05-19 2001-11-29 Barnes Jewish Hospital Enhanced triglyceride digestion in a deficiency of bile salts
EP1059041A1 (de) * 1999-06-07 2000-12-13 Universiteit Gent Kombinierte Verwendung von Triglyceriden mit mittelkettigen Fettsäuren und exogenen lipolytischen Enzymen als Futterzusätze
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
WO2004004757A1 (en) * 2002-07-02 2004-01-15 The Regents Of The University Of California Treatment for eye disorder
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
EP3299465A1 (de) 2003-03-07 2018-03-28 DSM IP Assets B.V. Hydrolasen, nukleinsäuren zur codierung davon und verfahren zur herstellung und verwendung davon
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
EP2216403A3 (de) 2006-02-02 2010-11-24 Verenium Corporation Esterasen und dazugehörige Nukleinsäuren und Verfahren
AR059692A1 (es) * 2007-03-01 2008-04-23 Adriana Fernandez Alimento de alto contenido calorico y de facil digestion
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
JP5850940B2 (ja) 2010-10-21 2016-02-03 スウェディッシュ オーファン バイオビトラム パブリーク アクチエボラグ ヒト乳児の発育速度を増大させる方法
CA2812852A1 (en) 2010-10-21 2012-04-26 Swedish Orphan Biovitrum Ab (Publ) Method to increase the absorption of unsaturated fatty acids by human infants
NZ716730A (en) 2012-02-17 2017-06-30 Alcresta Inc Methods, compositions, and devices for supplying dietary fatty acid needs
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
EP3432861B1 (de) 2016-03-24 2023-07-12 Elgan Pharma Ltd. Verwendung von insulin zur förderung der magenentleerung
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA662815A (en) * 1963-05-07 G. Farnham Merle Treatment for "scours" in mammals
US3256150A (en) * 1964-04-20 1966-06-14 Dairyland Food Lab Method for treating malabsorption syndrome
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
JPS5017559B2 (de) * 1972-09-20 1975-06-21
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2638089C2 (de) * 1976-08-24 1985-04-25 Degussa Ag, 6000 Frankfurt Lipase-Präparate mit verbesserter Wirkung
GB1571877A (en) * 1978-04-24 1980-07-23 Meito Sangyo Kk Microbial lipase and its preparation
JPS6047858B2 (ja) * 1978-09-20 1985-10-24 田村 輝 温浴用水製造装置
DE2923279C2 (de) * 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
ATE76561T1 (de) * 1985-01-09 1992-06-15 Genencor Inc Ueberfuehrung von exogenen stoffen in kaesebruch.
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase

Also Published As

Publication number Publication date
EP0317355A2 (de) 1989-05-24
ATE167982T1 (de) 1998-07-15
DE3856435T2 (de) 2001-03-29
ES2152941T3 (es) 2001-02-16
ES2120402T3 (es) 1998-11-01
DE3856214D1 (de) 1998-08-13
ATE197127T1 (de) 2000-11-15
JP2592939B2 (ja) 1997-03-19
JPH06315347A (ja) 1994-11-15
HK1023031A1 (en) 2000-08-25
US4944944A (en) 1990-07-31
DE3856214T2 (de) 1998-12-17
GR3035093T3 (en) 2001-03-30
EP0317355B1 (de) 1998-07-08
JPH01231848A (ja) 1989-09-18
HK1012213A1 (en) 1999-07-30
EP0605913B1 (de) 2000-10-25
EP0317355A3 (de) 1991-07-17
EP0605913A1 (de) 1994-07-13

Similar Documents

Publication Publication Date Title
DE3856435D1 (de) Verwendung von Gallsäure-aktiviertem Lipase als Diätsupplement
Bourre et al. Dietary linoleic acid and polyunsaturated fatty acids in rat brain and other organs. Minimal requirements of linoleic acid
Kinsell et al. Essential fatty acids, lipid metabolism, and atherosclerosis
AU628662B2 (en) Dietary supplement and method of minimizing effects of infection through diet
DK0515460T3 (da) Docosahexaensyre, fremgangsmåder til fremstilling deraf og forbindelser indeholdende samme
US20110223246A1 (en) Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
NL990032I1 (nl) Vetemulsie, werkwijze voor de bereiding daarvan ende toepassing daarvan.
DE3570362D1 (en) Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity
PT754001E (pt) Produto nutricional para tratamento da colite ulcerosa e sua utilizacao
IE791002L (en) Composition for total parenteral nutrition
KR20050111611A (ko) 아라키돈산의 하주일(下週日) 리듬 정상화용 용도
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
EP0409559A3 (en) Pharmaceutical and dietary uses of fatty acids
ES2037265T3 (es) Nuevo aceite dietetico.
JPS6466119A (en) Free fatty acid for treating diabetes
AU1489688A (en) Omega-3 fatty acids in traumatic injury treatment
Suttie et al. Fat utilization in the fluoride-fed rat
KR880010762A (ko) 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
Giampapa Diet and Aging
Zentler-Munro et al. Effect of cimetidine in pancreatic steatorrhoea
Sharmanov et al. Hypokinesia, nutrition and lipid metabolism. Lipids and lipoproteins in the blood
EP0187653A3 (en) Pharmaceutical compositions replacing the bile and aidinpharmaceutical compositions replacing the bile and aiding the digestion of fats, and process for their preparatig the digestion of fats, and process for their preparation on
Gibney Dietary essential fatty acids and peptic ulcer disease.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition